Prospective Single Arm Study on the Effect of Ilaprazole in Patients with Heartburn but No Reflux Esophagitis
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Patients with gastroesophageal reflux disease without esophagitis show varying responses to proton pump inhibitors(PPIs). The aim of this study was to objectively evaluate the effect of a new PPI, ilaprazole, on patients with heartburn but withoutreflux esophagitis. Materials and Methods: This prospective study was performed on 20 patients with heartburn but without reflux esophagitis. Allpatients underwent upper endoscopy and 24-hr combined multichannel intraluminal impedance and pH esophageal monitoring(MII-pH). They were then treated with ilaprazole (20 mg) once daily for 4 weeks. The GerdQ questionnaire, histologic findings,and inflammatory biomarkers were used for assessment before and after ilaprazole. Results: Among the 20 patients, 13 (65%) showed GerdQ score ≥8. Based on MII-pH results, patients were classified as true nonerosivereflux disease (n=2), hypersensitive esophagus (n=10), and functional heartburn (n=8). After treatment, patients showeda statistically significant improvement in GerdQ score (p<0.001). Among histopathologic findings, basal cell hyperplasia, papillaryelongation, and infiltration of intraepithelial T lymphocytes improved significantly (p=0.008, p=0.021, and p=0.008; respectively). Expression of TNF-α, IL-8, TRPV1, and MCP-1 decreased marginally after treatment (p=0.049, p=0.046, p=0.045, andp=0.042; respectively). Conclusion: Daily ilaprazole (20 mg) is efficacious in improving symptom scores, histopathologic findings, and inflammatorybiomarkers in patients with heartburn but no reflux esophagitis.
Abstract
Purpose: Patients with gastroesophageal reflux disease without esophagitis show varying responses to proton pump inhibitors(PPIs). The aim of this study was to objectively evaluate the effect of a new PPI, ilaprazole, on patients with heartburn but withoutreflux esophagitis. Materials and Methods: This prospective study was performed on 20 patients with heartburn but without reflux esophagitis. Allpatients underwent upper endoscopy and 24-hr combined multichannel intraluminal impedance and pH esophageal monitoring(MII-pH). They were then treated with ilaprazole (20 mg) once daily for 4 weeks. The GerdQ questionnaire, histologic findings,and inflammatory biomarkers were used for assessment before and after ilaprazole. Results: Among the 20 patients, 13 (65%) showed GerdQ score ≥8. Based on MII-pH results, patients were classified as true nonerosivereflux disease (n=2), hypersensitive esophagus (n=10), and functional heartburn (n=8). After treatment, patients showeda statistically significant improvement in GerdQ score (p<0.001). Among histopathologic findings, basal cell hyperplasia, papillaryelongation, and infiltration of intraepithelial T lymphocytes improved significantly (p=0.008, p=0.021, and p=0.008; respectively). Expression of TNF-α, IL-8, TRPV1, and MCP-1 decreased marginally after treatment (p=0.049, p=0.046, p=0.045, andp=0.042; respectively). Conclusion: Daily ilaprazole (20 mg) is efficacious in improving symptom scores, histopathologic findings, and inflammatorybiomarkers in patients with heartburn but no reflux esophagitis.
참고문헌 (34)
- Dent J, "Epidemiology of gastro-oesophageal reflux disease: a systematic review", Gut, 54, pp.710~717 (2005)[DOI]
- Dent J, "Microscopic esophageal mucosal injury in nonerosive reflux disease", Clin Gastroenterol Hepatol, 5, pp.4~16 (2007)[DOI]
- Savarino E, "NERD: an umbrella term including heterogeneous subpopulations", Nat Rev Gastroenterol Hepatol, 10, pp.371~380 (2013)[DOI]
- Savarino E, "The role of nonacid reflux in NERD: lessons learned from impedance- pH monitoring in 150 patients off therapy", Am J Gastroenterol, 103, pp.2685~2693 (2008)[DOI]
- Dean BB, "Effectiveness of proton pump inhibitors in nonerosive reflux disease", Clin Gastroenterol Hepatol, 2, pp.656~664 (2004)[DOI]
- Ji XQ, "Efficacy of ilaprazole in the treatment of duodenal ulcers: a meta-analysis", World J Gastroenterol, 20, pp.5119~5123 (2014)[DOI]
- Periclou AP, "A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease", Clin Pharmacol Ther, 68, pp.304~311 (2000)[DOI]
- de Bortoli N, "The pharmacokinetics of ilaprazole for gastroesophageal reflux treatment", Expert Opin Drug Metab Toxicol, 9, pp.1361~1369 (2013)[DOI]
- Du YQ, "Acid inhibition effect of ilaprazole on Helicobacter pylori-negative healthy volunteers: an open randomized cross-over study", J Dig Dis, 13, pp.113~119 (2012)[DOI]
- Fiocca R, "Development of consensus guidelines for the histologic recognition of microscopic esophagitis in patients with gastroesophageal reflux disease: the Esohisto project", Hum Pathol, 41, pp.223~231 (2010)[DOI]
- Yerian L, "Refinement and reproducibility of histologic criteria for the assessment of microscopic lesions in patients with gastroesophageal reflux disease: the Esohisto Project", Dig Dis Sci, 56, pp.2656~2665 (2011)[DOI]
- Weusten BL, "The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data", Gastroenterology, 107, pp.1741~1745 (1994)[DOI]
- Ward BW, "Ambulatory 24-hour esophageal pH monitoring. Technology searching for a clinical application", J Clin Gastroenterol, 8(Suppl 1), pp.59~67 (1986)[DOI]
- Tielemans MM, "Online follow-up of individuals with gastroesophageal reflux disease using a patient-reported outcomes instrument: results of an observational study", BMC Gastroenterol, 13, pp.144~ (2013)[DOI]
- Tielemans MM, "Open access capture of patients with gastroesophageal reflux disease using an online patient-reported outcomes instrument", Interact J Med Res, 1, pp.e7~ (2012)[DOI]
- Suzuki H, "Validation of the GerdQ questionnaire for the management of gastrooesophageal reflux disease in Japan", United European Gastroenterol J, 1, pp.175~183 (2013)[DOI]
- Quigley EM, "Non-erosive reflux disease, functional heartburn and gastroesophageal reflux disease; insights into pathophysiology and clinical presentation", Chin J Dig Dis, 7, pp.186~190 (2006)[DOI]
- Savarino E, "Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients", J Gastroenterol, 47, pp.159~168 (2012)[DOI]
- Long JD, "Nonerosive reflux disease: a pathophysiologic perspective", Curr Gastroenterol Rep, 10, pp.200~207 (2008)[DOI]
- Stolte M, "Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus", Scand J Gastroenterol, 35, pp.1125~1130 (2000)[DOI]
- Vieth M, "What parameters are relevant for the histological diagnosis of gastroesophageal reflux disease without Barrett's mucosa?", Dig Dis, 22, pp.196~201 (2004)[DOI]
- Kandulski A, "Histomorphological differentiation of non-erosive reflux disease and functional heartburn in patients with PPI-refractory heartburn", Aliment Pharmacol Ther, 38, pp.643~651 (2013)[DOI]
- Funch-Jensen P, "Microscopic appearance of the esophageal mucosa in a consecutive series of patients submitted to upper endoscopy. Correlation with gastroesophageal reflux symptoms and macroscopic findings", Scand J Gastroenterol, 21, pp.65~69 (1986)
- Kiesslich R, "Minimal change esophagitis: prospective comparison of endoscopic and histological markers between patients with non-erosive reflux disease and normal controls using magnifying endoscopy", Dig Dis, 22, pp.221~227 (2004)[DOI]
- Farre R, "Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal non-exposed human oesophagus", Gut, 59, pp.164~169 (2010)[DOI]
- Caviglia R, "Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure", Am J Gastroenterol, 100, pp.543~548 (2005)[DOI]
- Isomoto H, "Immune and inflammatory responses in GERD and lansoprazole", J Clin Biochem Nutr, 41, pp.84~91 (2007)[DOI]
- Isomoto H, "Enhanced expression of interleukin-8 and activation of nuclear factor kappa-B in endoscopy-negative gastroesophageal reflux disease", Am J Gastroenterol, 99, pp.589~597 (2004)[DOI]
- Monkemuller K, "Interleukin-1beta and interleukin-8 expression correlate with the histomorphological changes in esophageal mucosa of patients with erosive and non-erosive reflux disease", Digestion, 79, pp.186~195 (2009)[DOI]
- Shieh KR, "Evidence for neurotrophic factors associating with TRPV1 gene expression in the inflamed human esophagus", Neurogastroenterol Motil, 22, pp.971~977 (2010)[DOI]
- Isomoto H, "Elevated levels of chemokines in esophageal mucosa of patients with reflux esophagitis", Am J Gastroenterol, 98, pp.551~556 (2003)[DOI]
- Isomoto H, "Mucosal concentrations of proinflammatory cytokines and chemokines at gastric cardia: implication of Helicobacter pylori infection and gastroesophageal reflux", Am J Gastroenterol, 99, pp.1063~1068 (2004)[DOI]
- Yoshida N, "Interleukin-8 expression in the esophageal mucosa of patients with gastroesophageal reflux disease", Scand J Gastroenterol, 39, pp.816~822 (2004)[DOI]
- Noordzij JP, "Evaluation of omeprazole in the treatment of reflux laryngitis: a prospective, placebo-controlled, randomized, double-blind study", Laryngoscope, 111, pp.2147~2151 (2001)[DOI]
